3.13 Conjunctivitis, Viral, Non-Herpetic
Date of last review:
19/12/2025
Date of next review:
19/12/2027
Date of publication:
19/1/2026
This is a GOS Specialist Supplementary condition and should be managed by community optometrists in line with national guidance (8). This guideline should be read in conjunction with ‘Supporting information’ guidance [link to Supporting Information page]
Differential diagnosis (1)
-
Bacterial conjunctivitis
-
Chlamydial conjunctivitis
-
Gonococcal conjunctivitis
-
Herpes Simplex or Zoster conjunctivitis
-
Allergic conjunctivitis
Possible management by optometrist
Advice (1)
-
Wash hands or use gloves; disinfect equipment/surfaces
-
Avoid reusable tonometer prisms
-
Follow College infection control guidance
-
Self-limiting condition (resolves in 1–2 weeks)
-
Highly contagious – avoid sharing towels, close contact
-
Health/social care workers should avoid patient-facing roles for 2 weeks post-onset
-
No school/nursery exclusion unless outbreak
-
Stop contact lens use during acute phase
-
Monitor for corneal involvement or pseudomembrane formation
-
Antibacterial and antiviral agents (for adenovirus) are not effective
Treatment
-
Use cold compresses for relief (1)
-
Ocular lubricants for symptomatic relief as required (drops/gel for use during the day ± unmedicated ointment for use at bedtime) (1). Refer to local formularies for suitable options (6)
-
Topical antihistamines may be used for severe itching (1)
-
Steroid use for subepithelial infiltrates (SEI):
-
Consider low-potency steroids (e.g. fluorometholone) for persistent SEI >6 weeks (1)
-
Typical adult dosage/duration
(Blue text = IP, black text = non-IP)
-
Fluorometholone 0.1% eye drops (1,5) (POM): One drop (7), two to four times daily. For more serious conditions the dose can be increased to every hour for 24-48 hours, then reduce to four times daily (2,3). Duration will depend on severity of the condition and may require tapering (6).
-
Olopatadine 1mg/ml eye drops (1,5) (POM, off-label): One drop twice daily, max duration 4 months (2,3)
Regimens should be adjusted according to severity and patient factors (e.g. age, weight, pregnancy, renal function). Prescribing should follow local formulary and national guidance where available (7).
In cases of known sensitivities, please consult local formularies for alternative options (7).
Further management options
-
Normally no referral (1) GOS Specialist Supplementary Stage 1 where appropriate* (8)
-
If required, GOS Specialist Supplementary Stage 2* treatment should be provided by a local IP optometrist/OMP who is registered and qualified to carry out GOS Specialist Supplementary Stage 2 management; intra-referral (practice to practice) should take place to facilitate this (8)
-
Treatment may be provided within available locally enhanced schemes, or by community IP optometrists/OMPs, as appropriate (outwith GOS Specialist Supplementary) (7)
*Treatment should be provided in line with “Annex C of the Statement” (8) https://www.eyes.nhs.scot/for-professionals/legislation/
Possible management in secondary care or local/community pathways where available
-
See Further management options
College of Optometrists Clinical Management Guideline (1)
Conjunctivitis (viral, non-herpetic) - College of Optometrists *
*With special thanks to The College of Optometrists for providing the evidence framework for diagnosis and management from the Clinical Management Guidelines (CMGs) for this condition. All references to the College/CMGs are included where appropriate and form the basis of the Community Eyecare Guidelines.
Guidance is informed by the following sources
-
College of Optometrists Clinical Management Guidelines Clinical Management Guidelines - College of Optometrists
-
Advisory alignment with the College of Optometrists Formulary Optometrists' Formulary - College of Optometrists
-
Advisory alignment with the BNF BNF (British National Formulary) | NICE
-
Advisory alignment with the Summary Product Characteristics taken from the EMC Home - electronic medicines compendium (emc)
-
Advisory alignment with Scottish Health Board formularies (where a clear majority is present) *
-
Advisory alignment with expert consensus (CEGG), informed by sources 2-5 above
-
Advisory alignment with expert consensus (CEGG)
-
“Annex C of the Statement” https://www.eyes.nhs.scot/for-professionals/legislation/
* Scottish formularies should be available within the Prescribing section of your Health Board pages on the eyes.nhs.scot website. If unavailable, contact your local Health Board for further information; Health Boards landing page
If you have a query relating to this page, please email NSS.ComEyecareGuidelineGroup@nhs.scot